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SUMMARY – Th e aim of the study was to explore predictive value of the ALBI, PALBI and 
MELD scores on survival in patients resected for hepatocellular carcinoma with compensated liver 
cirrhosis and no macrovascular infi ltration. In this retrospective study, longitudinal survival analysis 
was performed. We analyzed patient/tumor characteristics and MELD, ALBI and PALBI scores as 
liver function tests for predicting survival outcome. Survival was analyzed from the date of liver resec-
tion until death, liver transplantation, or end of follow-up. Patients were stratifi ed for age, cirrhosis 
etiology, presence of esophageal varices, hepatocellular carcinoma stage, microvascular invasion, histo-
logic diff erentiation, and resection margins. We identifi ed 38 patients (alcoholic cirrhosis in 84.2% of 
patients) resected over an 8-year period. Median preoperative MELD score was 8, ALBI score -2.63, 
and PALBI score -2.38. During the follow-up period, 24 patients died. Estimated median survival 
time was 36 months. Microvascular invasion was observed in 33 patients. Higher ALBI score was as-
sociated with 23.1% higher relative risk of death. PALBI score was associated with 12.1% higher rela-
tive risk of death, whereas MELD score was not associated with the risk of death. In conclusion, ALBI 
score demonstrated signifi cant predictive capabilities for survival in patients with compensated cir-
rhosis resected for hepatocellular carcinoma.
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Introduction
Hepatocellular carcinoma (HCC) is a complex dis-
ease with many contributing factors and poor overall 
prognosis1. Currently, data report a 5-year overall sur-
vival of 50% for curative treatment of HCC2. Patient 
age, size and number of tumors, vascular invasion, his-
tologic grading, and portal vein invasion have all been 
demonstrated to infl uence recurrence after surgery3-5. 
Prognostic modeling in HCC is complex because un-
derlying diseases and residual liver function should be 
taken into account. Th e Barcelona Clinic Liver Cancer 
(BCLC) classifi cation is most commonly used in clin-
ical practice6-8. According to BCLC, hepatic curative 
resection might be achieved in patients with early 
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stage HCC, provided normal clinical performance sta-
tus and preserved liver function [bilirubin levels <1 
mg/dL, absence of portal hypertension, and Child-
Pugh (C-P) class – A status]2,9. C-P classifi cation was 
developed to stratify perioperative risk for patients 
with cirrhosis undergoing various types of surger-
ies10,11. Due to its subjective variables, it has proved to 
be of variable reliability12,13. Th e Model for End-Stage 
Liver Disease (MELD) score is a more sophisticated 
tool developed initially to assess the perioperative risk 
in cirrhotic candidates for transjugular intrahepatic 
portosystemic shunt (TIPS), and is based on objective 
measurements (serum creatinine, total bilirubin, inter-
national normalized ratio and serum sodium)14,15. Lat-
er on, it proved valuable in predicting outcome for 
other surgical procedures in these patients13. In this 
setting, its prognostic value is superior to that of the 
C-P classifi cation and has also been suggested for risk 
stratifi cation in HCC patients16,17. Over the past sev-
eral years, however, a new scoring system has been de-
veloped specifi cally in patients with HCC. Based on 
observational and clinical trial data in HCC patients 
from Europe, Japan and China, a score based on serum 
albumin and bilirubin (ALBI) was developed and 
shown to be able to identify diff erent risk patient sub-
sets within the C-P grade A18. Based on this score, pa-
tients are graded as grade 1 (lowest mortality risk) 
(ALBI score ≤2.60), ALBI grade 2 (score -2.60 < and 
≤1.39) (intermediate mortality risk) and grade 3 (score 
>-1.39) (highest mortality risk)18. Th e score was shown 
to perform well at diff erent C-P grades, diff erent tu-
mor sizes or tumor stages, and across diff erent treat-
ment modalities18,19. An extension of ALBI is PALBI 
score20 that additionally includes platelet count as an 
indicator of portal hypertension. Based on PALBI, pa-
tients are classifi ed as grade 1 (score ≤2.53), grade 2 
(score -2.53 < and ≤2.09) and grade 3 (score >-2.09). 
In one study, PALBI was suggested to better predict 
mortality in HCC patients across diff erent stages and 
treatment modalities than ALBI, and both scores were 
superior to MELD19. So far, ALBI was extensively 
evaluated in respect to predicting mortality and/or 
posthepatectomy liver failure after HCC treatment 
(resection, ablation, transarterial chemoembolization, 
systemic therapy) in mixed European-Japanese-Chi-
nese cohorts18 or Japanese or Chinese cohorts21,22. In 
one study, ALBI was found to be an independent pre-
dictor of progression-free survival, but not overall sur-
vival22, whereas in another one it better predicted pos-
thepatectomy liver failure than C-P classifi cation21. 
Specifi cs of these major studies were that they includ-
ed patients both with and without macrovascular in-
volvement (reported prevalence 7.8%-39%)18,19, some 
with diff erent C-P grades, or with HCC but not cir-
rhotic, and with prevailing hepatitis B or hepatitis C 
etiologies of cirrhosis18,19,23. Obviously, ALBI and its 
extension PALBI have a potential of risk stratifi cation 
in HCC patients, but it is also clear that further valida-
tion is needed since their performance might diff er 
depending on the underlying disease and/or other re-
gional specifi cs. In Croatia, being a southern-middle 
European country, alcohol abuse is the most prevalent 
cause of cirrhosis/HCC24,25. With this in mind, and 
considering that the best candidates for curative resec-
tion are C-P grade A patients, without macrovascular 
tumor infi ltration3, we undertook an exploratory eval-
uation of ALBI in relation to PALBI and MELD as 
predictors of overall survival in a cohort of Croatian 
HCC patients with C-P grade A cirrhosis without 
macrovascular involvement.
Patients and Methods
Ethics and general design
Th is single-center, retrospective analysis was based 
on a prospectively assembled institutional database on 
HCC patients and was approved by the institutional 
Ethics Committee.
Patients
Candidates for inclusion were patients with HCC 
and compensated (C-P grade A) liver cirrhosis that 
underwent curative tumor resection (with the indica-
tion based on the BCLC system) between January 1, 
2006 and July 31, 2014, in whom macrovascular infi l-
tration was positively excluded.
Patient evaluations and follow-up
Preoperatively, patients were assessed for etiology 
of liver disease; presence of ascites was assessed using 
ultrasound and imaging modalities (computed tomog-
raphy (CT) or magnetic resonance (MRI)); presence 
of esophageal varices was assessed on endoscopy; a 
C-P grade was assigned10; and MELD score was de-
termined16. Total tumor mass was defi ned as the sum 
of all tumor diameters; vascular infi ltration was de-
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fi ned as the presence of tumor thrombus in any he-
patic or portal vein based on CT or MRI. Presence of 
extrahepatic metastases was also analyzed based on 
CT or MRI. After the surgery, patients were followed-
up according to the standards of good practice in line 
with the professional guidelines7. For the purpose of 
the present analysis, patients were followed-up until 
death or liver transplantation (censored) as assessed 
from the database, and all others were contacted dur-
ing the second half of December 2015 and were treat-
ed as censored if alive, or death dates were obtained 
from the next of kin. ALBI and PALBI scores were 
calculated from the archived laboratory work-up. 
ALBI score= (log10 bilirubin x 0.66) + (albumin x 
-0.085)18. PALBI score=(2.02 x log10 bilirubin) - 
[0.37 x (log10 bilirubin)2] - (0.04 x albumin) – (3.48 x 
log10 platelets) + [1.01 x (log10 platelets)2,20.
Surgical procedure
Th e approach to the liver was through right sub-
costal ‘J’ laparotomy, followed by liver mobilization. 
Intraoperative ultrasonography (US) was used to iden-
tify the exact localization of the tumor and its relation-
ship to blood vessels. Th ese data were important to 
determine the type of liver resection. Liver resection 
was performed by blunt-clamp dissection technique, 
which allows visualization of intrahepatic vessels and 
individual ligation of major blood vessels or bile ducts. 
It was performed with the use of the LigaSure device 
(Medtronic, Covidien, USA)26,27. In all patients, inter-
mittent Pringle maneuver was used to avoid blood loss 
during liver transection.
Pathological analysis
Resected specimens were routinely formalin fi xed, 
paraffi  n embedded and stained by hemalaun-eosin 
(HE). HE slides were analyzed for histologic grade, 
presence of tumor-free margins and microvascular in-
vasion. Histologic grade was determined using the 
2010 WHO classifi cation28. Tumor free margins were 
measured on routine HE slides as the shortest distance 
from tumor border to the liver parenchyma resection 
margin inked by tissue dye. Microscopic vascular inva-
sion (mVI) was defi ned as tumor within a vascular 
space lined by the endothelium that was visible only by 
microscopy. A minimum of 5 HE slides from the tran-
sition zone between tumor and peritumoral liver pa-
renchyma were examined by two expert pathologists 
to determine mVI. Furthermore, one section of non-
tumoral liver tissue, which was most distant from tu-
mor tissue, was also examined for mVI29.
Data analysis
Data analysis was guided by the need to achieve a 
reasonably meaningful evaluation of predictivity of 
liver function scores within a limited sample size. 
Th erefore, the Cox proportional hazard models had to 
be carefully built. In this respect, and in order to avoid 
aliasing between potential baseline predictors, the fi rst 
step was to evaluate univariate associations between 
subject/tumor characteristics, apart from tumor size 
and liver function scores (or their elements), and sur-
vival. Th e second step was to investigate the relation-
ship between tumor size and liver function tests, and 
between tumor size, liver function tests and potentially 
identifi ed univariate survival predictors. In the fi rst 
step, only the Eastern Cooperation Oncology Group 
(ECOG) performance status was found to be associ-
ated with survival. In the second step, higher tumor 
size was found to be associated with worse ALBI and 
PALBI scores, and worse ECOG status was found to 
be associated with a larger tumor size, worse ALBI 
and worse PALBI scores. Th erefore, fi nal analysis was 
performed as follows: (a) the impact of tumor size on 
survival was assessed in a Cox model with adjustment 
for age and mVI (Model 1). No adjustment was done 
for ECOG status since worse ECOG was associated 
with larger tumor size; (b) the impact of ALBI score 
on survival was assessed in a Cox model with the same 
adjustments (Model 2); ECOG was skipped for the 
same reason as in Model 1. Th e model did not adjust 
for tumor size because (i) the main evaluation of 
ALBI18 was done without adjustment for tumor size, 
and (ii) larger tumor size was associated with worse 
ALBI; (c) the impact of PALBI was assessed in a Cox 
model (Model 3) with the same adjustments as in 
Model 2 (and for the same reasons); and (d) the im-
pact of MELD (Model 4) was assessed under the same 
conditions as the impact of ALBI and PALBI.
Results
Patient characteristics
Of the 42 patients that underwent liver resection 
for HCC during the index period, four patients were 
classifi ed as C-P stage B (one also having macroscopic 
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vascular invasion), hence 38 patients were included in 
the analysis. Table 1 summarizes their characteristics. 
Men prevailed, in line with the fact that virtually the 
only cause of cirrhosis was ethanol abuse (n=32). Th eir 
physical status was overall satisfactory, since 31 had 
ECOG performance status 0 or 1, while ascites and 
esophageal varices were sporadic. Total tumor mass 
varied between 30 and 240 mm and eight patients had 
extrahepatic involvement. Stage 1 and 2 (n=29) and 
poorly or moderately diff erentiated tumors (n=28) 
prevailed. In most patients (n=33), mVI was observed. 
ALBI score values ranged between -4.03 and -1.16. 
Considering the small sample, subjects were not cate-
gorized by ALBI grade, but 20 patients had values cor-
responding to ALBI grade 1 (≤2.60), 17 had values 
fi tting ALBI grade 2 (-2.60 < and ≤1.39) and one 
 patient had a score to fi t ALBI grade 3. Similarly, 
PALBI score ranged between -3.41 and -1.23, where 
13 patients had values fi tting grade 1 (≤2.53), 18 fell 
within grade 2 (-2.53 < and ≤2.09) and seven fi tted 
grade 3. MELD score range was 6-14, with seven pa-
tients with values >10.
Table 1. Characteristics of study patients (N=38)
Demographics Laboratory tests 
Age (yrs) 66 (39-82) Total bilirubin (mmol/L) 13 (7.1-36.3)
Men, n (%) 29 (76%) Albumin (g/L) 40 (25.0-54.3)
Clinical presentation International norm. ratio 1.1 (0.9-2.1)
Etiology of cirrhosis, n (%) Aspartate aminotransferase (U/L) 47 (14-281)
Ethanol abuse 32 (84.2%) Alanine aminotransferase (U/L) 42 (5-260)
Hepatitis B virus 2 (5.2%) Platelets (x109/L) 194 (90-495)
Hepatitis C virus 3 (7.8%) Liver function scores
Fatty liver 1 (2.6%) ALBI -2.63 (-4.03- -1.16)
ECOG performance status, n (%) PALBI -2.38 (-3.41- -1.23)
0 7 (18.4%) MELD 8 (6-14)
1 24 (63.2%) Follow-up and survival
2 5 (13.2%) Cumulative deaths 24 (63.2%)
3 2 (5.2%) Time to 1st death (months) 0.5
Ascites, n 4 (10.5%) Time to last death (months) 62
Esophageal varices, n (%) 5 (13.1%) Time to 1st censoring (months) 6
Tumor characteristics Time to last censoring (months) 57
Total tumor mass (mm); median(range) 85 (30-240)
Extrahepatic involvement, n (%) 8 (21.1%)




HCC histologic grade, n (%)
Poorly diff erentiated 3 (7.8%)
Moderately diff erentiated 25 (65.7%)
Well diff erentiated 10 (26.3%)
Microvascular invasion, n (%) 33 (86.8%)
Free resection margins, n (%) 26 (68.4%)
Data are expressed as medians (range from minimum to maximum) or number (n) and percentage (%) of participants per group; ECOG = 
Eastern Cooperation Oncology Group; ALBI = albumin-bilirubin; PALBI = platelet-albumin-bilirubin; MELD = model for end-stage 
liver diseases; HCC = hepatocellular carcinoma; HCC stage (1 – within Milan; 2 – outside Milan but no vascular infi ltration or extrahe-
patic metastasis; 3 – presence of vascular infi ltration or extrahepatic metastasis intraoperatively)
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Survival not accounting for tumor size 
and liver function scores
Overall, 24 (63.2%) patients died during the ob-
served period and estimated median survival was 36 
months (Fig. 1). First death occurred 0.5 months after 
the surgery and time of the last observed death was 62 
months (Table 1). Two patients were censored at the 
time of liver transplantation – one 6 months after re-
section (shortest censored time) and another one after 
16 months. Both were alive at the end-of-follow up 
date (December 31, 2015). Not counting tumor size 
and liver function scores (or elements used for their 
calculation), in this limited sample only ECOG per-
formance status was univariately associated with sur-
vival: all seven patients with ECOG 2 or 3 died during 
the observed period (estimated median survival 11 
months), while 17/31 with ECOG 0 or 1 died (esti-
mated median survival 41 months) – age-adjusted 
HR=2.86 (95% CI 1.06-6.98; p=0.039).
Relationship between diff erent liver function tests, 
tumor size and ECOG status
With adjustment for age, higher tumor size was as-
sociated with higher (worse) ALBI and PALBI scores, 
and no association was observed with MELD score 
(Table 2). Also, higher (worse) ECOG status (2 or 3 vs. 
1 or 0) was univariately associated with larger tumor 
size and higher (worse) ALBI and PALBI scores (Table 
3). No association was found with MELD score.
Exploration of the ALBI, PALBI 
and MELD predictive value
Considering the interrelationships observed be-
tween tumor size, liver function scores and ECOG 
Fig. 1. Kaplan-Meier product-limit survival curve 
summarizing survival in the observed cohort. 
Open circles above the line indicate censored observations; 
full circles in-between the curve indicate deaths
Table 2. Partial bivariate correlations (age-adjusted) between tumor size and liver function scores 
(Pearson correlation coeffi  cients and p-values) 
Tumor size ALBI PALBI MELD
Tumor size (mm) 1.000 0.356; 0.031 0.408; 0.012 0.065; 0.701
ALBI score --- 1.000 0.855; <0.001 0.367; 0.025
PALBI score --- --- 1.000 0.412; 0.011
ALBI = albumin-bilirubin; PALBI = platelet-albumin-bilirubin; MELD = model for end-stage liver diseases
Table 3. Tumor size, albumin-bilirubin (ALBI), platelet-albumin-bilirubin (PALBI) and model 
for end-stage liver disease (MELD) score values by patient subset based on Eastern Cooperation 
Oncology Group (ECOG) performance status 
ECOG 2-3 (n=7) ECOG 0-1 (n=31) Diff erence (95% CI); p-value*
Tumor size (mm) 120; (52-200) 75 (30-240) 40 (0 to 79); 0.057
ALBI score -2.13±0.63 -2.68±0.58 0.55 (0.05 to 1.05); 0.031
PALBI score -2.04±0.51 -2.47±0.39 0.43 (0.08 to 0.78); 0.017
MELD score 8 (6-13) 7 (6-14) 1 (-1 to 2); 0.411
Data are medians (range from minimum to maximum) or mean ± SD. Depicted are unadjusted diff erences between 
the two subsets with 95% confi dence intervals (CI); *Median diff erence (approximately 95.1% CI) by Mann-Whitney 
test for tumor size and MELD score, mean diff erence by t-test for ALBI and PALBI scores
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status, indicating that these variables to a great extent 
aliased each other, the following approach was imple-
mented: age and mVI were included into each model; 
then a separate model was fi tted to estimate the eff ect 
of tumor size, ALBI score, PALBI score and MELD 
score. With adjustment for age and mVI, tumor size 
was a strong predictor of death (Table 4); a 10 mm 
increase in tumor size was associated with 24.7% high-
er relative risk of death. Increase (‘worsening’) in ALBI 
score by 0.2 units was associated with a similar eff ect, 
i.e. 23.1% higher relative risk of death (Table 4). In-
crease (‘worsening’) in PALBI score (by 0.2 units) was 
associated with 12.1% higher relative risk of death, but 
the eff ect did not attain statistical signifi cance (Table 
4). Increase in MELD did not appear to be associated 
with the risk of death (Table 4).
Discussion
Results of this study revealed tumor size and ALBI 
score as strong predictors of postoperative survival in a 
cohort of Croatian patients with compensated, mostly 
alcoholic liver cirrhosis resected for HCC. ALBI score 
appeared superior to PALBI and MELD in this set-
ting. Our cohort was interesting because alcohol abuse 
was the predominant cause of cirrhosis and macrovas-
cular invasion was excluded preoperatively. Th is is im-
portant due to geographical diff erences in HCC pa-
tient profi les. Since the prevailing data on this issue 
come from Asia where the etiologic factors for HCC 
are diff erent (viral causes predominate), our data could 
be interesting for the European population since alco-
hol is a more prevalent cause of chronic liver disease in 
this area30. Factors predicting survival after liver resec-
tion for HCC include tumor stage (tumor size, histo-
logic grade, presence of vascular invasion and metasta-
sis), surgical technique (achievement of free resection 
margins), residual liver function, as well as the pres-
ence and severity of portal hypertension3,31. Not count-
ing tumor size and liver function scores, in this limited 
sample only ECOG performance status was univari-
ately associated with survival. However, higher ECOG 
performance status signifi cantly correlated with the 
ALBI and PALBI scores, whereas no association was 
found with the MELD score. Also, larger tumor size 
was associated with higher ALBI and PALBI, but not 
higher MELD. Th e impact of other variables on sur-
vival such as the presence of mVI, presence of esopha-
geal varices, and extension of liver resection could not 
be assessed from this small sample data since the 
 majority of patients were positive or negative for each 
of these categories, leaving only few patients available 
for comparison and making statistical evaluation un-
reliable. Th e signifi cant prognostic value of ECOG 
performance status is not surprising taking into ac-
count signifi cant aliasing with tumor size and liver 
function scores. Multivariate modeling identifi ed total 
tumor mass as a strong predictor of death with each 10 
mm increase in size being associated with 24.7% 
 higher relative risk of death in our cohort (Table 4). In 
addition to this, 27/38 (73.7%) tumors were moder-
ately to poorly diff erentiated. According to literature 
data, tumor size and high histologic grade are predic-
tors of mVI31 and presence of extrahepatic metasta-
ses32. Indeed, mVI and extrahepatic metastases were 
Table 4. Association between tumor size, ALBI score, 
PALBI score and MELD score with the risk of all-cause 
death. Four separate Cox proportional hazard models 
were fi tted to time-to event data in the observed cohort 
successively testing the risk associated with increasing 
tumor size, ALBI score, PALBI score and MELD score, 
with adjustment for age and microvascular invasion 
(see Patients and Methods – Data analysis for details on 
model building)
HR (95% CI) p-value
Model 1
Tumor size (by 10 mm) 1.247 (1.116-1.407) <0.001
Age (by 5 years) 0.956 (0.811-1.147) 0.611





Age (by 5 years) 0.886 (0.725-1.097) 0.248





Age (by 5 years) 0.936 (0.778-1.147) 0.462





Age (by 5 years) 0.960 (0.797-1.177) 0.683
Microvascular invasion 4.554 (1.215-29.9) 0.022
ALBI = albumin-bilirubin; PALBI = platelet-albumin-bilirubin; 
MELD = model for end-stage liver diseases
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detected in 33/38 (86.8%) and 3/38 (7.8%) of our 
 patients, respectively. Such a high prevalence of mVI 
and metastases could account for the poorer overall 
 estimated survival time of 36 months observed in our 
study, and could indicate poor patient stratifi cation at 
enrolment. According to literature data, HCC with 
mVI is found in 35% of cases and the prevalence of 
lymph node metastases below the diaphragm is 2% to 
3%29,30. Free resection margins were achieved in 68.4% 
of patients, we speculate due to the high median tumor 
mass found in this cohort. At the time of diagnosis, 
liver function was evaluated using the C-P score and 
MELD score. All of the patients resected were C-P 
class A and had median MELD score 8. Th e biggest 
drawback of the C-P score refers to patients who fall 
around the cutoff  points, which are arbitrary, who may 
thus be classifi ed as having a diff erent risk. Johnson et 
al.17 found that log
10 
bilirubin and albumin were con-
sistently statistically signifi cant predictors of survival. 
When C-P grade A patients were reclassifi ed into 
ALBI grade 1 or 2, there was a 10-month diff erence in 
survival between the two ALBI grades18. When incor-
porated into the BCLC system, the performance of 
ALBI grades was similar to the C-P system in a mul-
ticenter study with the majority of patients coming 
from Japan and China. Nevertheless, ALBI upstaged 
4.8% of HCC patients and survival diff erence between 
the restaged patients was signifi cant22. Th e median 
ALBI score in our data was -2.63. When adjusted for 
age and mVI ‘worsening’ ALBI score was associated 
with 23.1% higher relative risk of death (Table 4). 
When compared with data reported by Johnson et 
al.18, our data show a similar eff ect of ALBI grade on 
survival in adjustment to tumor size. With liver func-
tion ranging from ALBI -4.03 to -1.16, it is clear that 
our cohort of patients was indeed very heterogeneous 
and that C-P is not sensitive enough to further stratify 
these patients. Together with the burden of tumor size, 
these fi ndings could explain diff erence in survival 
 observed in our cohort (shortest and longest time from 
surgery to death 0.5 and 62 months, respectively). 
 Although PALBI score was associated with 12.1% 
higher relative risk of death when adjusted for tumor 
size and mVI, the eff ect did not attain statistical sig-
nifi cance in our cohort and MELD was not associated 
with the risk of death at all (Table 4). Th is may have 
been expected since both PALBI and MELD contain 
additional components to assess the risk across the 
worsening liver function stages. Namely, PALBI in-
cludes platelets as the indicator of portal hypertension, 
and MELD score is specifi cally designed for patients 
with end-stage cirrhosis (not representative for HCC 
patients considering liver resection)33,34. On the other 
hand, ALBI was originally calculated in the cohort of 
only C-P A patients without clinically signifi cant por-
tal hypertension to subclassify them according to the 
odds of survival following liver resection for HCC. 
Our cohort encompassed only C-P A patients without 
signs of clinically signifi cant portal hypertension de-
tected during preoperative work-up, which may have 
been the reason for not to expect signifi cant impact of 
PALBI and MELD score on survival. However, this 
hypothetical conclusion is not strongly funded since 
our results arised from a small number of patients. 
Th erefore, it might be worthy to explore, at least for 
PALBI, its performance on a larger cohort of patients 
with compensated C-P A cirrhosis without macrovas-
cular infi ltration, since some data suggest not so deci-
sive impact of portal hypertension on survival follow-
ing liver resection for HCC35. As for MELD, previous 
studies revealed both lower mortality and reduced 
morbidity in patients undergoing liver resection for 
HCC when MELD score was <914. Besides the previ-
ously mentioned limitations, MELD score is infl u-
enced greatly by creatinine level and therefore not nec-
essarily indicative of deterioration in liver function32. 
Th e main limitation to our work was the small number 
of patients analyzed. For this reason, we were unable to 
perform more complex and informative multivariate 
analysis of diff erent prognostic factors such as esopha-
geal varices, ascites, number of segments resected and 
their eff ect on patient survival in comparison to ALBI 
score. In conclusion, tumor mass and ALBI score are 
strong predictors of outcome in patients resected for 
HCC and appear superior to PALBI and MELD 
score in predicting postoperative survival in patients 
with compensated cirrhosis with no macrovascular in-
fi ltration.
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Sažetak
INDEKS ALBI KAO PREDIKTOR PREŽIVLJENJA NAKON RESEKCIJE 
HEPATOCELULARNOG KARCINOMA U BOLESNIKA S KOMPENZIRANOM CIROZOM JETRE: 
USPOREDBA S INDEKSIMA PALBI I MELD
T. Božin, S. Mustapić, T. Bokun, L. Patrlj, M. Rakić, G. Aralica, M. Kujundžić, V. Trkulja i I. Grgurević
Cilj je bio istražiti prediktivnu vrijednost zbira ALBI, PALBI i MELD za preživljenje bolesnika s kompenziranom ciro-
zom reseciranih zbog hepatocelularnog karcinoma bez makrovaskularne invazije. Provedena je retrospektivna longitudinalna 
analiza preživljenja. Testirane su karakteristike bolesnika/tumora kao i jetreni funkcijski testovi MELD, ALBI i PALBI za 
predviđanje preživljenja. Bolesnici su praćeni nakon resekcije jetre do smrti, transplantacije jetre odnosno do kraja vremena 
praćenja. Bolesnici su kategorizirani po dobi, etiologiji ciroze, prisutnosti varikoziteta jednjaka, stadiju karcinoma, mikrova-
skularnoj invaziji, histološkom stadiju i resekcijskim rubovima. Identifi cirali smo 38 bolesnika (alkoholna ciroza kod 84,2% 
bolenika) reseciranih kroz razdoblje od 8 godina. Medijan prijeoperacijskog zbira MELD bio je 8, zbira ALBI -2,63 i zbira 
PALBI -2,38. Tijekom praćenja 24 bolesnika su umrla. Očekivani medijan preživljenja iznosio je 36 mjeseci. Mikrovaskular-
na invazija pronađena je u 33 bolesnika. Veći ALBI je bio povezan s 23,1%, a PALBI s 12,1% većim relativnim rizikom od 
smrtnog ishoda. MELD nije bio povezan sa smrtnim ishodom. Zbir ALBI je pokazao značajnu prediktivnu vrijednost 
 preživljenja u skupini bolesnika s kompenziranom cirozom reseciranih zbog hepatocelularnog karcinoma.
Ključne riječi: karcinom, hepatocelularni; jetrena ciroza; jetra, ispitivanje funkcije; hepatektomija; jetra, transplantacija; ezofa-
gusni i želučani varikoziteti; jetrena ciroza, alkoholna; kontrolne studije; preživljavanje
